🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 15/10/2009 | 34,17 | 35,49 | 34,08 | 35,26 | +2,74% | 4,13% | 2.532.000 |
| 14/10/2009 | 33,84 | 34,58 | 33,65 | 34,32 | +2,08% | 2,75% | 2.187.900 |
| 13/10/2009 | 33,51 | 33,87 | 33,40 | 33,62 | +0,48% | 1,40% | 1.347.300 |
| 12/10/2009 | 34,00 | 34,15 | 33,32 | 33,46 | -0,86% | 2,44% | 1.282.300 |
| 09/10/2009 | 33,14 | 33,84 | 32,87 | 33,75 | +1,78% | 2,93% | 2.282.300 |
| 08/10/2009 | 34,13 | 34,14 | 33,00 | 33,16 | -1,75% | 3,34% | 2.517.100 |
| 07/10/2009 | 33,75 | 34,14 | 33,47 | 33,75 | +0,00% | 1,99% | 1.934.500 |
| 06/10/2009 | 34,00 | 34,60 | 33,19 | 33,75 | -0,09% | 4,15% | 1.939.200 |
| 05/10/2009 | 35,02 | 35,37 | 33,78 | 33,78 | -3,46% | 4,54% | 3.184.100 |
| 02/10/2009 | 34,58 | 35,61 | 34,36 | 34,99 | +2,28% | 3,61% | 2.947.500 |
| 01/10/2009 | 36,88 | 37,06 | 34,21 | 34,21 | -9,74% | 7,73% | 4.797.500 |
| 30/09/2009 | 37,71 | 38,15 | 37,00 | 37,90 | +0,29% | 3,05% | 1.217.800 |
| 29/09/2009 | 37,68 | 38,00 | 37,20 | 37,79 | +0,27% | 2,12% | 1.704.900 |
| 28/09/2009 | 36,65 | 37,77 | 36,40 | 37,69 | +3,57% | 3,74% | 1.108.900 |
| 25/09/2009 | 36,13 | 36,87 | 35,97 | 36,39 | +1,00% | 2,49% | 948.000 |
| 24/09/2009 | 36,56 | 36,65 | 35,51 | 36,03 | -1,29% | 3,12% | 992.200 |
| 23/09/2009 | 37,24 | 37,24 | 36,32 | 36,50 | -1,30% | 2,47% | 1.087.500 |
| 22/09/2009 | 38,17 | 38,17 | 36,83 | 36,98 | -2,97% | 3,51% | 1.401.700 |
| 21/09/2009 | 37,45 | 38,21 | 37,27 | 38,11 | +1,49% | 2,51% | 1.161.500 |
| 18/09/2009 | 37,89 | 38,19 | 37,25 | 37,55 | -1,05% | 2,48% | 2.454.500 |
| 17/09/2009 | 37,25 | 38,50 | 37,14 | 37,95 | +2,02% | 3,65% | 1.842.300 |
| 16/09/2009 | 36,91 | 37,21 | 36,44 | 37,20 | +0,59% | 2,09% | 1.694.800 |
| 15/09/2009 | 36,76 | 37,08 | 36,28 | 36,98 | +0,22% | 2,18% | 1.014.800 |
| 14/09/2009 | 35,76 | 36,91 | 35,75 | 36,90 | +2,73% | 3,24% | 899.400 |
| 11/09/2009 | 36,05 | 36,45 | 35,62 | 35,92 | -0,33% | 2,30% | 1.518.500 |
| 10/09/2009 | 36,90 | 37,07 | 35,81 | 36,04 | -2,38% | 3,41% | 2.100.300 |
| 09/09/2009 | 36,69 | 37,31 | 36,54 | 36,92 | +0,57% | 2,10% | 1.414.700 |
| 08/09/2009 | 36,31 | 36,81 | 35,87 | 36,71 | +1,07% | 2,59% | 934.000 |
| 04/09/2009 | 36,08 | 36,58 | 35,66 | 36,32 | +1,03% | 2,55% | 986.400 |
| 03/09/2009 | 36,07 | 36,07 | 35,33 | 35,95 | +0,28% | 2,05% | 1.151.900 |